NCT01170338Unknown4 期
Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- nicotine levels
研究概览
简要总结
Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •active smokers presenting to hospital with an acute coronary syndrome
排除标准
- •patients with an acute coronary syndrome who are not active smokers
研究组 & 干预措施
active Chantix
Experimental
active drug to help smoking cessation
干预措施: Varenicline 100 mg by mouth twice daily (Drug)
sugar pill
Placebo Comparator
干预措施: control (Drug)
结局指标
主要结局
nicotine levels
时间窗: 1 month
次要结局
- recurrent myocardial ischemia(1 month)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement TherapyTobacco DependenceNCT02355665McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.1,198
已完成
不适用
Efficacy and Safety Following Use of a Novel Nicotine Replacement TherapySmoking CessationNCT00882375McNeil AB479
已完成
不适用
Smoking Cessation After Acute Coronary SyndromeSmokingRecurrenceAcute Coronary SyndromeNCT03209622University of Monastir89
已完成
1 期
Clinical evaluation of the new nicotinic receptor marker (-)- [18F]NCFHEB with Positron Emission Tomography in Alzheimer’s disease patients, and healthy volunteersG30Alzheimer diseaseDRKS00000472niversität Leipzig49
已完成
3 期
Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit PatientsCovid19SARS-Associated Coronavirus as Cause of Disease Classified ElsewhereNCT04598594Assistance Publique - Hôpitaux de Paris220